ADC Therapeutics S.A.
ADCTNYSEHealthcare● Active
$1.03
$-0.29(-21.97%)
Market Cap$131006730
P/E Ratio—
52W High$4.98
52W Low$1.02
ADC Therapeutics S.A. (ADCT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADCT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $81.36M | $70.84M | $69.56M | $209.91M | $33.92M |
| Cost of Revenue | $7.67M | $5.95M | $2.53M | $3.30M | $1.39M |
| Gross Profit | $73.68M | $64.89M | $67.03M | $206.61M | $32.52M |
| Gross Margin %(computed) | 90.57% | 91.60% | 96.36% | 98.43% | 95.89% |
| Operating Expenses | |||||
| R&D Expenses | $104.00M | $109.63M | $127.13M | $186.46M | $158.00M |
| G&A Expenses | $36.56M | $64.47M | $72.88M | $107.74M | $71.46M |
| Total Operating Expenses | $182.06M | $195.54M | $233.01M | $329.95M | $294.24M |
| Operating Income | ($108.38M) | ($130.65M) | ($165.99M) | ($123.34M) | ($261.72M) |
| Operating Margin %(computed) | -133.21% | -184.44% | -238.63% | -58.76% | -771.65% |
| Interest Income | $8.81M | $12.27M | $10.54M | $2.57M | $0.07M |
| Interest Expense | $51.63M | $50.21M | $46.33M | $36.73M | $18.34M |
| Income Before Tax | ($142.78M) | ($157.68M) | ($200.95M) | ($156.90M) | ($251.50M) |
| Income Tax Expense | ($0.16M) | $0.17M | $39.11M | $0.23M | ($21.48M) |
| Net Income | ($142.62M) | ($157.85M) | ($240.05M) | ($157.13M) | ($230.03M) |
| Net Margin %(computed) | -175.31% | -222.83% | -345.11% | -74.86% | -678.20% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.12 | $-1.62 | $-2.94 | $-1.99 | $-3.00 |
| Wtd Avg Shares | 127.07M | 97.16M | 81.71M | 78.15M | 76.75M |
| EBITDA | ($106.50M) | ($102.65M) | ($145.83M) | ($107.70M) | ($230.53M) |
| EBITDA Margin %(computed) | -130.91% | -144.91% | -209.65% | -51.31% | -679.70% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more ADC Therapeutics S.A. data
About ADC Therapeutics S.A. (ADCT) Income Statement
ADC Therapeutics S.A. (ADCT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ADCT reported revenue of $0.08B, gross profit of $0.07B (gross margin 90.57%), and net income of ($0.14B) — a net profit margin of -175.31%.
Frequently asked questions
ADCT · 4 questionsADC Therapeutics S.A. (ADCT) reported revenue of $0.08B for 2025, up 14.9% year-over-year.
ADCT revenueADCT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08